HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $180
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Axsome Therapeutics (NASDAQ:AXSM) but lowers the price target from $190 to $180.

August 08, 2023 | 10:21 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Axsome Therapeutics' price target has been lowered from $190 to $180 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100